Publications by authors named "Ales Bartunek"
Article Synopsis
- The study focused on developing a new dasatinib formulation (anhydrate) to enhance absorption and reduce variability compared to the existing form (monohydrate) for treating chronic myeloid leukemia.
- In bioavailability comparisons, both formulations fell within the standard absorption range, with the anhydrate showing significantly lower variability in drug exposure among subjects.
- While omeprazole reduced dasatinib levels, it was deemed clinically irrelevant, highlighting the need for caution when co-prescribing despite prevalent use among patients.
One of the major concerns for all in vivo experiments is intra- and inter-subject variability, which can be a great source of inaccuracy. The aim of this study is, therefore, to estimate the ability of parallel vs. cross-over design studies in order to describe the relative pharmacokinetic performance of the studied drug formulations.
View Article and Find Full Text PDFIn this open-label, laboratory-blinded, 2-way single dose study in 24 volunteers of both sexes we found that (1) nabumetone reaches mean Cmax ± SD of 0.56 ± 0.20 mg·L at mean tmax of 8.
View Article and Find Full Text PDFBackground: Rosuvastatin, a synthetic lipid-lowering agent acts selectively by competitive inhibition of 3-hydroxy- 3-methylglutaryl-coenzyme A. It is indicated as an adjunct to diet in patients with hypercholesterolemia and mixed dyslipidemia.
Objective: The purpose of this study was to demonstrate bioequivalence between a generic rosuvastatin 40 mg tablet (Zentiva, Prague, Czech Republic) and a reference product (Crestor, AstraZeneca, Luton, UK), under fasting conditions as required by the European Medicinal Agency.